Analyst Price Targets — CING
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| August 23, 2026 10:06 pm | — | Roth Capital | $9.00 | $5.55 | TheFly | Cingulate price target lowered to $9 from $10 at Roth Capital |
| May 19, 2026 2:50 pm | Boobalan Pachaiyappan | Roth Capital | $10.00 | $4.41 | TheFly | Cingulate price target lowered to $10 from $14 at Roth Capital |
| May 19, 2025 1:00 am | Boobalan Pachaiyappan | Roth Capital | $11.00 | $3.82 | TheFly | Cingulate price target lowered to $11 from $12 at Roth Capital |
Latest News for CING
KANSAS CITY, Kan., Aug. 13, 2026 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform to develop a pipeline of next-generation products, today reported financial results for the quarter ended June 30, 2026, and provided a corporate update.
KANSAS CITY, Kan., Aug. 11, 2026 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company advancing next-generation pharmaceutical products through its proprietary Precision Timed Release™ (PTR™) drug delivery platform, today announced the publication of "Comparative Bioavailability of Trimodal CTx-1301 Versus Bimodal Dexmethylphenidate" in the peer-reviewed journal CNS Drugs.
Publication helps establish the efficacy and safety profile of of CTx-1301, reinforcing the potential of Cingulate's Precision Timed Release™ platform technology Publication helps establish the efficacy and safety profile of of CTx-1301, reinforcing the potential of Cingulate's Precision Timed Release™ platform technology
CEO Shane Schaffer: Inclusion Demonstrates Continued Growth and Enhanced Visibility Among Institutional Investors CEO Shane Schaffer: Inclusion Demonstrates Continued Growth and Enhanced Visibility Among Institutional Investors
KANSAS CITY, Kan., June 16, 2026 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform technology to build and advance a pipeline of next-generation pharmaceutical products, today announced the issuance of its first company-owned U.S. patent covering its lead asset, CTx-1301 (dexmethylphenidate HCl), for the…
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for CING.
U.S. House Trading
No House trades found for CING.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.